2
|
Kirst C, Tietze J, Ebeling M, Horndasch L, Karaghiosoff K. The Formation of P-C Bonds Utilizing Organozinc Reagents for the Synthesis of Aryl- and Heteroaryl-Dichlorophosphines. J Org Chem 2021; 86:17337-17343. [PMID: 34730367 DOI: 10.1021/acs.joc.1c01560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Aryl- and heteroaryl-dichlorophosphines are mildly and selectively made in a one-pot synthesis in moderate to good yields starting from the respective aryl bromides or five-membered heterocycles, following lithiation with nBuLi, transmetalation with ZnCl2, and subsequently the reaction with PCl3. Selected aryl- and heteroaryl-dichlorophosphines were successfully synthesized using this reaction method and could easily be purified after isolation. The intermediate formation of the organozinc species is essential, as it prevents the formation of multiple substitution products. Important are also the reaction conditions: the usage of the proper solvent for the respective aromatic precursors and removal of the remaining salts by addition of a dioxane/pentane mixture. Depending on the solvent and steric demand of the substituent, mono- and bis-substitution products can be formed but formation also prevented. Hereby, different organozinc species might play an important role.
Collapse
Affiliation(s)
- Christin Kirst
- Department of Chemistry, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13 (D), 81377 Munich, Germany
| | - Jonathan Tietze
- Department of Chemistry, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13 (D), 81377 Munich, Germany
| | - Marian Ebeling
- Department of Chemistry, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13 (D), 81377 Munich, Germany
| | - Lukas Horndasch
- Department of Chemistry, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13 (D), 81377 Munich, Germany
| | - Konstantin Karaghiosoff
- Department of Chemistry, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13 (D), 81377 Munich, Germany
| |
Collapse
|
3
|
Mainolfi N, Ehara T, Karki RG, Anderson K, Mac Sweeney A, Liao SM, Argikar UA, Jendza K, Zhang C, Powers J, Klosowski DW, Crowley M, Kawanami T, Ding J, April M, Forster C, Serrano-Wu M, Capparelli M, Ramqaj R, Solovay C, Cumin F, Smith TM, Ferrara L, Lee W, Long D, Prentiss M, De Erkenez A, Yang L, Liu F, Sellner H, Sirockin F, Valeur E, Erbel P, Ostermeier D, Ramage P, Gerhartz B, Schubart A, Flohr S, Gradoux N, Feifel R, Vogg B, Wiesmann C, Maibaum J, Eder J, Sedrani R, Harrison RA, Mogi M, Jaffee BD, Adams CM. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem 2020; 63:5697-5722. [PMID: 32073845 DOI: 10.1021/acs.jmedchem.9b01870] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.
Collapse
Affiliation(s)
- Nello Mainolfi
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Takeru Ehara
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Rajeshri G Karki
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Karen Anderson
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Aengus Mac Sweeney
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Sha-Mei Liao
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Upendra A Argikar
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Keith Jendza
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Chun Zhang
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - James Powers
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Daniel W Klosowski
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Maura Crowley
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Toshio Kawanami
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Jian Ding
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Myriam April
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Cornelia Forster
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Michael Serrano-Wu
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Michael Capparelli
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Rrezarta Ramqaj
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Catherine Solovay
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Frederic Cumin
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Thomas M Smith
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Luciana Ferrara
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Wendy Lee
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Debby Long
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Melissa Prentiss
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Andrea De Erkenez
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Louis Yang
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Fang Liu
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Holger Sellner
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Finton Sirockin
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Eric Valeur
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Paulus Erbel
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Daniela Ostermeier
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Paul Ramage
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Bernd Gerhartz
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Anna Schubart
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Stefanie Flohr
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Nathalie Gradoux
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Roland Feifel
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Barbara Vogg
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Christian Wiesmann
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Jürgen Maibaum
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Jörg Eder
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Richard Sedrani
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Richard A Harrison
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
| | - Muneto Mogi
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Bruce D Jaffee
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Christopher M Adams
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
4
|
Veillard F, Troxler L, Reichhart JM. Drosophila melanogaster clip-domain serine proteases: Structure, function and regulation. Biochimie 2015; 122:255-69. [PMID: 26453810 DOI: 10.1016/j.biochi.2015.10.007] [Citation(s) in RCA: 84] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 10/05/2015] [Indexed: 01/22/2023]
Abstract
Mammalian chymotrypsin-like serine proteases (SPs) are one of the best-studied family of enzymes with roles in a wide range of physiological processes, including digestion, blood coagulation, fibrinolysis and humoral immunity. Extracellular SPs can form cascades, in which one protease activates the zymogen of the next protease in the chain, to amplify physiological or pathological signals. These extracellular SPs are generally multi-domain proteins, with pro-domains that are involved in protein-protein interactions critical for the sequential organization of the cascades, the control of their intensity and their proper localization. Far less is known about invertebrate SPs than their mammalian counterparts. In insect genomes, SPs and their proteolytically inactive homologs (SPHs) constitute large protein families. In addition to the chymotrypsin fold, many of these proteins contain additional structural domains, often with conserved mammalian orthologues. However, the largest group of arthropod SP regulatory modules is the clip domains family, which has only been identified in arthropods. The clip-domain SPs are extracellular and have roles in the immune response and embryonic development. The powerful reverse-genetics tools in Drosophila melanogaster have been essential to identify the functions of clip-SPs and their organization in sequential cascades. This review focuses on the current knowledge of Drosophila clip-SPs and presents, when necessary, data obtained in other insect models. We will first cover the biochemical and structural features of clip domain SPs and SPHs. Clip-SPs are implicated in three main biological processes: the control of the dorso-ventral patterning during embryonic development; the activation of the Toll-mediated response to microbial infections and the prophenoloxydase cascade, which triggers melanization. Finally, we review the regulation of SPs and SPHs, from specificity of activation to inhibition by endogenous or pathogen-encoded inhibitors.
Collapse
Affiliation(s)
- Florian Veillard
- CNRS UPR9022, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France.
| | - Laurent Troxler
- CNRS UPR9022, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
| | - Jean-Marc Reichhart
- Faculté des Sciences de la Vie, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
5
|
trans-Protease activity and structural insights into the active form of the alphavirus capsid protease. J Virol 2014; 88:12242-53. [PMID: 25100849 DOI: 10.1128/jvi.01692-14] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The alphavirus capsid protein (CP) is a serine protease that possesses cis-proteolytic activity essential for its release from the nascent structural polyprotein. The released CP further participates in viral genome encapsidation and nucleocapsid core formation, followed by its attachment to glycoproteins and virus budding. Thus, protease activity of the alphavirus capsid is a potential antialphaviral target to arrest capsid release, maturation, and structural polyprotein processing. However, the discovery of capsid protease inhibitors has been hampered due to the lack of a suitable screening assay and of the crystal structure in its active form. Here, we report the development of a trans-proteolytic activity assay for Aura virus capsid protease (AVCP) based on fluorescence resonance energy transfer (FRET) for screening protease inhibitors. Kinetic parameters using fluorogenic peptide substrates were estimated, and the K(m) value was found to be 2.63 ± 0.62 μM while the k(cat)/K(m) value was 4.97 × 10(4) M(-1) min(-1). Also, the crystal structure of the trans-active form of AVCP has been determined to 1.81-Å resolution. Structural comparisons of the active form with the crystal structures of available substrate-bound mutant and inactive blocked forms of the capsid protease identify conformational changes in the active site, the oxyanion hole, and the substrate specificity pocket residues, which could be critical for rational drug design. IMPORTANCE The alphavirus capsid protease is an attractive antiviral therapeutic target. In this study, we have described the formerly unappreciated trans-proteolytic activity of the enzyme and for the first time have developed a FRET-based protease assay for screening capsid protease inhibitors. Our structural studies unveil the structural features of the trans-active protease, which has been previously proposed to exist in the natively unfolded form (M. Morillas, H. Eberl, F. H. Allain, R. Glockshuber, and E. Kuennemann, J. Mol. Biol. 376:721-735, 2008, doi:http://dx.doi.org/10.1016/j.jmb.2007.11.055). The different enzymatic forms have been structurally compared to reveal conformational variations in the active and substrate binding sites. The flexible active-site residue Ser218, the disordered C-terminal residues after His261, and the presence of a water molecule in the oxyanion hole of AVCPΔ2 (AVCP with a deletion of the last two residues at the C terminus) reveal the effect of the C-terminal Trp267 deletion on enzyme structure. New structural data reported in this study along with the fluorogenic assay will be useful in substrate specificity characterization, high-throughput protease inhibitor screening, and structure-based development of antiviral drugs.
Collapse
|
11
|
Wahab HA, Ahmad Khairudin NB, Samian MR, Najimudin N. Sequence analysis and structure prediction of type II Pseudomonas sp. USM 4-55 PHA synthase and an insight into its catalytic mechanism. BMC STRUCTURAL BIOLOGY 2006; 6:23. [PMID: 17076907 PMCID: PMC1636056 DOI: 10.1186/1472-6807-6-23] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2006] [Accepted: 11/01/2006] [Indexed: 12/01/2022]
Abstract
Background Polyhydroxyalkanoates (PHA), are biodegradable polyesters derived from many microorganisms such as the pseudomonads. These polyesters are in great demand especially in the packaging industries, the medical line as well as the paint industries. The enzyme responsible in catalyzing the formation of PHA is PHA synthase. Due to the limited structural information, its functional properties including catalysis are lacking. Therefore, this study seeks to investigate the structural properties as well as its catalytic mechanism by predicting the three-dimensional (3D) model of the Type II Pseudomonas sp. USM 4–55 PHA synthase 1 (PhaC1P.sp USM 4–55). Results Sequence analysis demonstrated that PhaC1P.sp USM 4–55 lacked similarity with all known structures in databases. PSI-BLAST and HMM Superfamily analyses demonstrated that this enzyme belongs to the alpha/beta hydrolase fold family. Threading approach revealed that the most suitable template to use was the human gastric lipase (PDB ID: 1HLG). The superimposition of the predicted PhaC1P.sp USM 4–55 model with 1HLG covering 86.2% of the backbone atoms showed an RMSD of 1.15 Å. The catalytic residues comprising of Cys296, Asp451 and His479 were found to be conserved and located adjacent to each other. In addition to this, an extension to the catalytic mechanism was also proposed whereby two tetrahedral intermediates were believed to form during the PHA biosynthesis. These transition state intermediates were further postulated to be stabilized by the formation of oxyanion holes. Based on the sequence analysis and the deduced model, Ser297 was postulated to contribute to the formation of the oxyanion hole. Conclusion The 3D model of the core region of PhaC1P.sp USM 4–55 from residue 267 to residue 484 was developed using computational techniques and the locations of the catalytic residues were identified. Results from this study for the first time highlighted Ser297 potentially playing an important role in the enzyme's catalytic mechanism.
Collapse
Affiliation(s)
- Habibah A Wahab
- Laboratory of Biocrystallography and Structural Bioinformatics, Universiti Sains Malaysia, Penang, Malaysia
- School of Pharmaceutical Sciences. Universiti Sains Malaysia, Penang, Malaysia
| | - Nurul Bahiyah Ahmad Khairudin
- Laboratory of Biocrystallography and Structural Bioinformatics, Universiti Sains Malaysia, Penang, Malaysia
- School of Pharmaceutical Sciences. Universiti Sains Malaysia, Penang, Malaysia
| | - Mohd Razip Samian
- Laboratory of Biocrystallography and Structural Bioinformatics, Universiti Sains Malaysia, Penang, Malaysia
- School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
| | - Nazalan Najimudin
- Laboratory of Biocrystallography and Structural Bioinformatics, Universiti Sains Malaysia, Penang, Malaysia
- School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
| |
Collapse
|